BioSpace News Archive

While cardiovascular disease remains the leading cause of death globally, new research led by NYU Grossman School of Medicine and Moi University School of Medicine found that addressing and incorporating social determinants of health in the clinical management of blood pressure in Kenya can improve outcomes for patients with diabetes or hypertension.

Global Industry Coalition Aims to Dramatically Increase Access for All Patient Populations in Clinical Trials and Research

Pressure BioSciences, Inc. (OTCQB: PBIO) today announced that the Company will host a teleconference to discuss its Fourth Quarter and Fiscal Year 2020 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay

As Long COVID brings renewed attention to the debilitating and chronic illness known as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a record number of advocates are virtually gathering on Capitol Hill for Solve M.E.'s 5th Annual Advocacy Week Monday, April 19.

Quadrant Biosciences Inc., a developer of novel molecular diagnostic tools, has been granted a Breakthrough Device designation by the Center of Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) for its innovative Clarifi ASD® autism saliva test.

David Hovland, Ph.D., to serve as Chief Regulatory Officer and Bryan Smith, J.D. as General Counsel, Corporate Secretary, and Chief Compliance Officer

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing pharmaceutical product candidates for pain management, today announced the results of an animal study model for MMS019, its anti-viral product candidate for respiratory viruses.

MyMD Pharmaceuticals, Inc. is pleased to announce that its common shares will begin trading , April 19th, on the NASDAQ Stock Market under the ticker symbol “MYMD.”.

WithHealth, Inc., a comprehensive precision-based telehealth provider, is pleased to announce that its services continue to enable companies and their employees to return to their workplaces in a safe production environment.

New Data Presented at 2021 American Academy of Neurology (AAN) Annual Meeting Shows VYEPTI® (eptinezumab-jjmr) Demonstrated Earlier Time to Freedom from Headache Pain and Absence of Most Bothersome Symptoms Compared to Placebo When Initiated During Migraine Attack in Patients Who Were Candidates for Preventive Therapy